CK2α Deficiency Drives Myocardial Fibrosis via Desmin-Induced Mitochondrial Dysfunction.

Area of Science:

• Cardiology
• Molecular Biology
• Cell Biology

Background:

• Myocardial fibrosis is a key feature of heart failure.
• The signals initiating fibrosis from cardiomyocytes are not well understood.
• Pathological crosstalk between cardiomyocytes and fibroblasts drives fibrosis.

Purpose of the Study:

• To identify early triggers of fibrotic remodeling originating from cardiomyocytes.
• To elucidate the molecular mechanisms linking cardiomyocyte dysfunction to fibroblast activation.
• To explore CK2α as a potential therapeutic target for fibrotic heart disease.

Main Methods:

• Investigated cardiomyocyte-specific CK2α loss in a mouse model.
• Analyzed mitochondrial function, proteome, and metabolic reprogramming.
• Examined the role of CK2α in Desmin phosphorylation and αB-crystallin recruitment.
• Utilized AAV9-mediated gene delivery to restore CK2α in cardiomyocytes.

Main Results:

• Cardiomyocyte CK2α downregulation caused mitochondrial collapse, metabolic failure, and sterile inflammation.
• CK2α loss led to impaired Desmin phosphorylation, disrupting mitochondrial quality control.
• This resulted in paracrine activation of cardiac fibroblasts via mediators like IL-6.
• Restoring cardiomyocyte CK2α ameliorated mitochondrial dysfunction and attenuated fibrosis.

Conclusions:

• CK2α downregulation in cardiomyocytes is an early trigger of fibrotic remodeling.
• A CK2α-Desmin-mitochondrial quality control axis is critical for cardiomyocyte health.
• Cardiomyocyte-intrinsic defects initiate paracrine signaling that drives fibroblast activation and fibrosis.
• Targeting this axis offers potential therapeutic strategies for fibrotic heart disease.